ChemotherapyFDA-approvedSecond-line
Trifluridine/tipiracil
How it works
Trifluridine is converted into FUTA in the body, which interferes with DNA replication and cell division, ultimately killing cancer cells.
Cancer types
Colorectal Cancer— All patients
Efficacy
Studies show that trifluridine/tipiracil can improve overall survival in patients with metastatic colorectal cancer who have failed prior therapies.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| New Treatment Combination Shows Promise for Metastatic Colorectal Cancer | Colorectal Cancer | phase-2 | The objective response rate was 18.3%, and the disease control rate was 83.3%. | Source → |
| Trifluridine/Tipiracil Treatment in Metastatic Colorectal Cancer | Colorectal Cancer | observational | Median overall survival was 7.59 months. | Source → |
| Trifluridine/Tipiracil Combinations Show Promise in Advanced Colorectal Cancer | Colorectal Cancer | review | Median overall survival ranged 8.6-14.4 months and median progression-free survival 3.7-6.8 months with FTD/TPI plus bevacizumab in refractory mCRC. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.